HC Wainwright Has Negative Estimate for CATX Q3 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities research analysts at HC Wainwright dropped their Q3 2025 earnings per share estimates for shares of Perspective Therapeutics in a research note issued on Monday, May 19th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.31) per share for the quarter, down from their previous forecast of ($0.30). HC Wainwright currently has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics' FY2025 earnings at ($1.17) EPS, Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.32) EPS.

CATX has been the subject of a number of other research reports. Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. Wedbush reissued an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 13th. Royal Bank of Canada reduced their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday, March 27th. Truist Financial cut their target price on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Finally, Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $12.50.

Perspective Therapeutics Price Performance

Shares of CATX traded down $0.12 during trading hours on Wednesday, hitting $2.39. The company had a trading volume of 656,911 shares, compared to its average volume of 1,036,003. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $16.70. The firm has a fifty day moving average price of $2.25 and a 200-day moving average price of $3.45.

Insider Buying and Selling at Perspective Therapeutics

In other news, Director Robert F. Williamson III purchased 22,192 shares of the business's stock in a transaction dated Friday, March 28th. The stock was acquired at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the acquisition, the director now directly owns 70,837 shares of the company's stock, valued at approximately $160,799.99. This represents a 45.62% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Juan Graham acquired 33,333 shares of the firm's stock in a transaction dated Friday, March 28th. The stock was bought at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the acquisition, the chief financial officer now owns 35,354 shares in the company, valued at approximately $79,546.50. The trade was a 1,649.33% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 115,696 shares of company stock valued at $256,344. Corporate insiders own 3.72% of the company's stock.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its stake in Perspective Therapeutics by 498.3% in the 4th quarter. JPMorgan Chase & Co. now owns 149,045 shares of the company's stock valued at $475,000 after buying an additional 124,133 shares during the period. Vontobel Holding Ltd. acquired a new stake in Perspective Therapeutics during the 4th quarter valued at $51,000. SG Americas Securities LLC increased its position in Perspective Therapeutics by 41.3% during the 4th quarter. SG Americas Securities LLC now owns 26,088 shares of the company's stock worth $83,000 after purchasing an additional 7,627 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Perspective Therapeutics during the fourth quarter worth about $688,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Perspective Therapeutics in the 4th quarter worth approximately $51,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.